Evidence map›Paper›PMID 41833244›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2026

Pharmacokinetic and pharmacodynamic properties of cannabigerol in male mice.

Alex Mabou Tagne, Faizy Ahmed, Adren Tran, Francesca Galvani, Lana Debbaneh, Emma Raine Perranoski, David Sarlah, Aditi Das, Elisa Pabon, Ziva Cooper and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alex Mabou TagneDepartment of Anatomy and Neurobiology, University of California, Irvine, Irvine, California; Department of Pharmaceutical Sciences, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Science Center, Amarillo, Texas.
Faizy AhmedDepartment of Anatomy and Neurobiology, University of California, Irvine, Irvine, California.
Adren TranDepartment of Anatomy and Neurobiology, University of California, Irvine, Irvine, California.
Francesca GalvaniDepartment of Anatomy and Neurobiology, University of California, Irvine, Irvine, California.
Lana DebbanehDepartment of Anatomy and Neurobiology, University of California, Irvine, Irvine, California.
Emma Raine PerranoskiDepartment of Anatomy and Neurobiology, University of California, Irvine, Irvine, California.
David SarlahDepartment of Chemistry, Rice University, Houston, Texas.
Aditi DasSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, Georgia.
Elisa PabonJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California; Jane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Ziva CooperJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California; Jane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry and Biobehavioral Sciences, Department of Anesthesiology and Perioperative Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.
Daniele PiomelliDepartment of Anatomy and Neurobiology, University of California, Irvine, Irvine, California; Department of Biological Chemistry, University of California Irvine, Irvine, California; Department of Pharmaceutical Sciences, University of California, Irvine, Irvine, California. Electronic address: piomelli@hs.uci.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cannabigerol (CBG) is a nonintoxicating phytocannabinoid gaining popularity as a self-medication for anxiety and other conditions; however, its pharmacological properties remain poorly defined. Here, we report the development of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for quantifying CBG and its primary oxidative metabolite, cyclo-CBG. This platform enabled the characterization of CBG's pharmacokinetic and biotransformation profile after intraperitoneal administration (10 mg/kg) in male mice. CBG exhibited rapid systemic distribution and clearance, with relatively low brain penetration (brain-to-plasma ratio = 0.26). In contrast, cyclo-CBG accumulated in brain tissue to a surprising extent (brain-to-plasma ratio = 7.1), suggesting local formation and a potentially important role in mediating central effects. Despite prior reports of anxiolytic effects, we found that CBG administered at its peak brain concentration produced anxiogenic-like effects in mice, as assessed using the elevated plus maze. This response was not affected by the CB

Indexed as

CannabinoidsAnimalsBrainChromatography, LiquidMaleMiceMice, Inbred C57BLTandem Mass SpectrometrycannabigerolCannabinoidsAnxietyCannabigerolCannabisCyclo-cannabigerolLiquid chromatography/tandem mass spectrometryPharmacokinetics

Identifiers

PMID41833244
PMCPMC13197944

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.